Background: The U.S. Food and Drug Administration has published new pregnancy and lactation labelling rules that set standards on the presentation of information with regard to drug usage during pregnancy and breastfeeding, as well as the effects on fertility. These guidelines became effective June 30, 2015, and classified the risks of using prescription drugs during pregnancy in three detailed subsections: Pregnancy, Lactation, and Females and Males of Reproductive Potential. These sections describe the risks within a real-world context of caring for these patients. Objective: In this study, we reclassified and categorized drugs and treatments commonly used in dermatology according to these new guidelines. Methods: We performed a search of the medical literature about the use of relevant prescription drugs during pregnancy and breastfeeding and their effect on fertility. The search included prospective and retrospective studies, review articles from PubMed-indexed journals (from inception to November 2018), U.S. Food and Drug Administration records, pregnancy exposure registries, relevant information and studies provided in drug labeling by companies, and updated pharmacologic texts and guidelines up to 2018. Results: Topical immunomodulators, systemic immunomodulators (including biologics), systemic antipruritic agents, antimicrobials, as well as acne, hair, and cosmetic agents were included. We have made best attempts to review and consolidate existing and new data and include them in our guide. Conclusion: This new narrative format facilitates prescribing by considering a variety of factors. One previously overlooked aspect was the impact on the reproductive potential of both male and female patients. Rather than depending on overly simplistic letter risk categories, dermatologists will now need to make prescribing decisions based on each patient and the information provided, which will allow for better decision making and patient care.
Introduction
Dermatologists often encounter pregnant or breastfeeding women seeking professional advice on skin disorders. Female patients may become pregnant during the course of treatment of their dermatological conditions. Hence, dermatologists must be familiar with the potential effects of common medications on the fetus and nursing infant.
However, the generalizations of the old category system (i.e., A, B, C, D, and X), together with the lack of safety data, make assessments of risks versus benefits difficult. Therefore, the U.S.
Topical immunomodulators

Topical corticosteroids
Most large, population-based studies have not found any significant associations between maternal use of topical corticosteroids and pregnancy outcomes. Mild-to-moderate potency topical corticosteroids are preferred, and usage should be limited to a short duration because large amounts of very potent topical steroids during pregnancy has been associated with low-birth-weight babies ( Chi et al., 2016 ) . It is recommended that lactating mothers avoid application to the breast and nipple-areolar area until nursing ceases.
Non-steroid immunomodulators
Information on topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), imiquimod, calcipotriene, and crisaborole is shown in Table 1 .
Systemic immunomodulators
Information on systemic immunomodulators is shown in Table 2 .
Systemic corticosteroids
Use of the lowest effective steroid dose is recommended ( Briggs et al., 2014 ) . These drugs should be avoided during the first trimester when the fetus's hard palate is forming. The use of corticosteroids during lactation is deemed "usually compatible" by the American Academy of Paediatrics if justified by a potential benefit to the mother. Delaying nursing until 3 to 4 hours after treatment with high doses is recommended to minimize infant exposure.
Other systemic immunomodulators
Hydroxychloroquine, cyclosporine, and sulfasalazine are relatively low risk during pregnancy and lactation. Acitretin, methotrexate, cyclophosphamide, mycophenolate mofetil, and thalidomide should be avoided under all circumstances. We recommend two forms of contraception per the FDA black box warning guidelines. In addition, male patients on thalidomide should also use a latex condom during sexual contact with women of childbearing potential, even after a successful vasectomy. Counseling should be offered in the event of inadvertent exposure. The use of systemic therapy with conditions such as psoriasis should be discussed extensively with the pregnant patient because psoriasis may improve spontaneously in up to 60% of pregnant women.
We also included the new Janus kinase inhibitor tofacitinib, which is currently indicated for psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Apremilast, a phosphodiesterase 4 inhibitor, is currently indicated for moderate-to-severe plaque psoriasis and psoriatic arthritis. 
Tacrolimus and pimecrolimus
Limited data on female reproduction.
Limited clinical data available on the effects of topical tacrolimus and pimecrolimus during pregnancy, lactation, and reproduction. Due to its large molecular size, pimecrolimus is theoretically poorly absorbed systemically. When no alternatives exist, topical use on small surfaces is permissible . Oral tacrolimus is associated with low birth weight and premature birth; hence, avoidance in topical form is recommended.
Excretion of both drugs in breast milk is less than levels used for infantile organ rejection; however, the effects on infants are unknown and caution is advised. Using sparingly and avoiding application on the nipple are recommended .
Data based on animal rodent studies from manufacturer indicate altered sex hormone functions with pimecrolimus at high doses (20-40 times maximum human exposure after dermal application), and reduced sperm function was noted in male rats at high subcutaneous doses of tacrolimus. Rodent studies showed no change in reproduction and fertility in both males and females ( Suzuki et al., 1996 ) . Limited clinical data are available in humans.
Rodent studies showed no change in reproduction and fertility in both males and females.
‡ Limited clinical data are available in humans. Crisaborole ( Eucrisa package insert, 2016 ) No available data with crisaborole in pregnant women to inform of drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, no adverse developmental effects were observed with the oral administration of crisaborole in pregnant rats and rabbits during organogenesis at doses up to 5 and 3 times, respectively, the maximum recommended human dose
No information available on the presence of crisaborole in human milk, effects of the drug on the breastfed infant, or effects of the drug on milk production after topical application of crisaborole to women who are breastfeeding.
Crisaborole is systemically absorbed.
Limited data are available. Limited data are available. and avoidance during first trimester when hard palate of the fetus is forming recommended. Recent studies have not shown increased risk of cleft deformities ( Bandoli et al., 2017 ) . Exposure during pregnancy may increase risk of premature rupture of membrane, placental insufficiency, low birth weight, and intrauterine growth restriction in babies. * Systemic corticosteroids are excreted into breast milk. Use of corticosteroids during lactation is deemed "usually compatible" by AAP if justified by potential benefit to the mother . Nursing delay recommended for 3-4 hours after high doses to minimize infant exposure.
Possible theoretical reversible decrease in sperm production and motility; however, discontinuation not necessary in male patients trying to conceive ( Semet et al., 2017 ) .
Limited data on women; however, oral corticosteroids are used as part of in vitro fertilization and infertility treatments for women.
Azathioprine
Conflicting results from transplant and inflammatory bowel disease studies. Use if benefit of immunosuppression appears to outweigh risks.
May be compatible with breastfeeding. Recommendation to wait 4 hours after ingesting medication and monitor infant full blood count. †
No recommendation to discontinue for male patients while trying to conceive. Case series on 18 patients did not show decrease in sperm quality ( Dejaco et al., 2001 ).
Limited data.
Acitretin U.S. boxed warning : Contraindicated, known teratogen. Two forms of contraception advised, with avoidance of pregnancy 3 years after discontinuation.
Excreted in breast milk. Avoid due to potential cumulative toxicity. †
No reported infertility cases; no alterations in sperm counts/motility ( Millsop et al., 2013 ) .
Limited data available.
Cyclophosphamide
Risk of teratogenicity in humans high, especially if used during first trimester ( Briggs et al., 2014 ) . Causes cyclophosphamide embryopathy (growth restriction, ear and facial abnormalities, absence of digits, hypoplastic limbs, and developmental delay).
Excreted in breast milk. Avoid. High risk of permanent azoospermia.
Cryopreservation of sperm necessary before treatment ( Silva et al., 2010 ) .
Risk of infertility related to cumulative dose and age ( Janssen and Genta, 2000 ) .
Cyclosporine
No increased rate of fetal major malformations compared with the general population. ‡ Animal data suggest low risks. Associated with low birth weight and prematurity in babies of patients with complicated health status. If used, minimum dose should be administered with close monitoring of maternal blood pressure and renal function.
Enters breast milk, not recommended by AAP.
No recommendation to discontinue for male patients while trying to conceive. ‡ Study showed normal semen parameters and testicular function ( Haberman et al., 1991 ) .
Hydroxychloroquine
Can be continued during pregnancy and lactation to prevent disease flares.
Deemed compatible by AAP. Limited data available, not well studied.
Hydroxyurea
Contraindicated. Teratogenicity and embryotoxicity in animals. No adequate human studies.
Excreted in breast milk. Avoid. Small retrospective study in male patients showed potentially irreversible decreased sperm motility and spermatogenesis ( Grigg, 2007 ) .
Limited data on female fertility.
Intravenous immunoglobulin
Compatible in pregnancy. * Limited studies have shown intravenous immunoglobulin to be a safe therapy in pemphigus and pemphigoid gestationis ( Ahmed and Gurcan, 2011 Reversible oligospermia, asthenozoospermia, and teratozoospermia in male patients ( Toovey et al., 1981 Adequate and well-controlled studies with apremilast have not been conducted in pregnant women. In animal studies, the administration of apremilast to cynomolgus monkeys during organogenesis resulted in doserelated increases in abortion/embryofetal death at dose exposures of 2.1 × MRHD, and no adverse effect at an exposure of 1.4 × MRHD. In mice, no apremilast-induced malformations were observed at exposures up to 4.0 × MRHD. Incidences of malformation and pregnancy loss in human pregnancies have not been established for apremilast.
Unknown whether apremilst or its metabolites are present in human milk; however, apremilast was detected in milk of lactating mice.
In fertility study of male mice, apremilast at oral doses up to approximately 3 × MRHD produced no effects on male fertility.
In fertility study of female mice, apremilast was administered at oral doses of 10, 20, 40, or 80 mg/kg/day. At doses ≥ 1.8 × MRHD, estrous cycles were prolonged due to lengthening of diestrus, resulting in longer intervals until mating. Mice that became pregnant at doses of ≥ 20 mg/kg/day also had in- 
Biologics
Biologics ( Table 3 ) are relatively new, specific systemic therapies. Although there are no large scale studies, an increasing body of evidence suggests that biologics can be used in the treatment of patients with psoriasis during pregnancy and lactation because psoriasis as a disease itself is a risk factor for adverse pregnancy outcomes. Anti-tumor necrosis factor (TNF) alpha agents are preferred over IL-12/23 and IL-17 inhibitors due to the increased availability of long-term data. Recommendations include using anti-TNF alpha agents during the first half of pregnancy and discontinuing during the third trimester due to risks of disseminated infection in infants who receive live vaccinations. Anti-TNF alpha agents (except certolizumab) are IgG1 antibodies or receptors attached to an Fc portion of an IgG1. In the third trimester, there is a marked increase in IgG1 placental transfer ( Eworuke et al., 2019 ) . Adalimumab and infliximab are both IgG1 immunoglobulins, but etanercept is a fusion protein with considerably less transplacental transport.
Certolizumab is an Fc-free, PEGylated TNF-alpha inhibitor that is approved for treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Certolizumab has an FDA label update indicating minimal active placental and breastmilk transfer due to its lack of the Fc region. It should be considered for pregnant women who require a biologic.
Breastfeeding is generally acceptable during treatment with anti-TNF alpha agents because these agents are minimally excreted in breast milk. Live vaccines should be avoided for 6 months in infants whose mothers have been continuously exposed to biologics, due to increased risks of infections ( Porter et al., 2017 ) .
We also included newer biologics such as guselkumab, ixekizumab (indicated for psoriasis), and dupilumab (indicated for treatment of atopic dermatitis and asthma).
Systemic antipruritics
Antihistamines
The preferred choices in pregnancy is diphenhydramine and chlorpheniramine due to their long history of relatively uneventful use during pregnancy. Loratadine is preferred as a nonsedating antihistamine as it poses no major teratogenic risk. Otherwise, cetirizine may also be considered. Observation for symptoms of sedation, tachycardia, or dry mouth in the nursing infant is recommended.
There are no published animal studies examining the effects of antihistamines on male fertility, and current available literature on humans reports conflicting findings. There are a few case reports of gynecomastia, low sperm motility, and inability to conceive associated with chronic antihistamine use, and these effects were reversible 3 months after antihistamine discontinuation. However, a Adalimumab No apparent evidence of increased embryotoxicity, teratogenicity, or pregnancy loss based on data from > 500 pregnancies ( Grunewald and Jank, 2015 ) . Manufacturer recommends contraception during therapy and within 5 months after end of treatment.
Case reports show no adverse effects on infants .
Limited clinical data suggest no negative impact on male/female fertility.
Etanercept
Multiple studies (cohort, case controls, registry data, case reports) of > 300 pregnancies conclude no patterns of malformation or prematurity ( Götestam Skorpen et al., 2016 ) . Generally preferred over other anti-tumor necrosis factor alpha agents due to its fusion protein makeup. An exception to these general conclusions is 1 case report of an infant with VACTERL * association in a mother on etanercept during pregnancy ( Carter et al., 2006 ) . Concentration excreted in breast milk minimal; no adverse events reported.
No negative effects on fertility. In men, spermiogram parameters remained unchanged ( Clark, 2010 ) .
No negative effects on fertility.
Infliximab
Multiple studies of > 1000 pregnancies do not show patterns of malformation or prematurity ( Ostensen, 2014 ) . Manufacturer recommends contraception during therapy and for 6 months after last infusion.
Case reports show no adverse effects on the infant. †
In vitro experiments show decreased sperm motility and sperm integrity ( Perdichizzi et al., 2007 ) . However, normal ejaculate findings remained unchanged in patients on infliximab ( Villiger et al., 2010 ) and a small case series have described births of healthy children to fathers who were on infliximab during the time of conception ( Paschou et al., 2009 ).
Limited clinical data. Does not appear to be affected.
Ixekizumab
Extremely limited clinical data, no human studies. One animal study showed no harmful effects on the fetus when medication was administered during the first 20 weeks of gestation; week 20 to birth was associated with increased neonatal deaths ( Clarke et al., 2015 ) .
Excretion in breast milk unknown.
Limited data. Preclinical animal studies do not show impairment on male and female fertility.
Omalizumab
Limited data in pregnant women; use has been mainly reported in population with asthma.
Limited data. Preclinical animal studies show no effect on male/female fertility.
Limited data. Preclinical animal studies show no effect on male/female fertility. Rituximab Not recommended. Counseling recommended for women to avoid pregnancy for at least 12 months after exposure due to long retention time.
|
Excreted in breast milk. Avoid. † Limited data. Eight case reports in literature of men on rituximab at the time of conception; 7 of 8 pregnancies resulted in healthy children, and 1 was a spontaneous abortion ( Ostensen, 2014 .
Excreted in small amounts in breast milk, but studies have not shown any adverse effects. Compatible .
No impairment of fertility based on animal studies. Limited data in humans. Per manufacturer, animal studies in rats showed reduced sperm motility and reduced embryo implantations at oral doses much higher than systemic exposure in humans (17×).
Limited data in humans. Per manufacturer, animal studies in rats showed reduced sperm motility and reduced embryo implantation at oral doses much higher than systemic exposure in humans (17×). Erythromycin Antibiotic of choice throughout pregnancy, along with penicillins. Erythromycin estolate causes maternal hepatotoxicity during second trimester, and contraindicated during pregnancy.
Deemed compatible by AAP. † Human clinical study on 78 men showed no significant effect on semen quality ( Baker et al., 1984 ) .
Fluoroquinolones (ciprofloxacin, ofloxacin)
Generally avoided during pregnancy and lactation because they are toxic to developing cartilage in experimental animal studies, but not found in human pregnancy.
* Accidental administration should not be indication for abortion.
Ciprofloxacin and ofloxacin considered safe for lactation by AAP; watch for diarrhea.
Per manufacturer, animal studies with high doses (13×) showed decreased spermatogenesis and impaired fertility in male rats. However, multiple studies have demonstrated antibiotic therapy recommendations for testicular infections and epididymis ( Briggs et al., 2014 ) .
No effects on fertility observed in female rats.
Metronidazole
Human data suggest low risks. Topical usage is permissible ( Burtin et al., 1995 ) .
Deemed compatible. †
Animal studies on rats showed male infertility at high doses ( el-Nahas and elAshmawy, 2004 ). Limited clinical data in humans.
Mupirocin (topical)
Low dose use has not been associated with teratogenicity in small studies.
Compatible. Topical antibiotic of choice during lactation.
Limited clinical data in humans. Animal studies show no effect on fertility.
Limited clinical data in humans. Animal studies show no effect on fertility. Penicillins (penicillin G, penicllin V, amoxicillin, ampicillin, cloxacillin)
Antibiotic of choice during pregnancy. Excreted into breast milk in low concentrations. Reports of loose stools and rash in nursing infants. Use with caution.
In vitro studies showed no effect on sperm characteristics at low doses. Impairment in viability at higher doses.
Retapamulin (topical) Animal studies have shown minor effects on fetal growth and incomplete ossification after oral administration. However, very low plasma concentration suggests little to no risks with topical application. ‡ Excretion in breast milk unknown.
Animal studies showed no impairment of male/female fertility.
Animal studies showed no impairment of male/female fertility. Mixed results in male in vitro studies ( Samplaski and Nangia, 2015 ) . No impairment on fertility based on animal studies.
No impairment on fertility based on animal studies.
Tetracyclines
Contraindicated; risk of congenital defects. * Recommendation to avoid prolonged usage for > 3 weeks to prevent infant dental staining. †
In vitro study showed reversible impairment of sperm movement and viability ( Millsop et al., 2013 ) .
Limited data available. Animal studies show no effect on fertility. Animal studies show no effect on fertility.
Topical antifungal
Antiviral
Acyclovir
No reported association with adverse fetal effects in human pregnancy ( Stone et al., 2004 ) .
Deemed compatible by AAP. † Manufacturer's animal studies using high doses of acyclovir showed largely reversible adverse effects on spermatogenesis. Limited data in humans.
Manufacturer's animal rodent studies show no effect in female fertility. Limited data in humans. Famciclovir Limited data available. Use when potential benefit clearly outweighs fetal risk in human pregnancy. Acyclovir and valacyclovir preferred.
Testicular toxicity noted in manufacturer's animal studies. No effect on sperm count and morphology in human male clinical study.
No effect on fertility in manufacturer's female rodent animal studies.
Valacyclovir Prodrug of acyclovir. Guidelines for use as in acyclovir.
Second-line therapy. Manufacturer product information showed no effect on fertility in animal studies.
Manufacturer product information showed no effect on fertility in animal studies. Animal rodent study showed slight male fertility disturbances ( el-Nahas and elAshmawy, 2008 ). Rodent animal studies by manufacturer did not show any impairment of fertility.
Antiscabetic/antipediculocide
Lindane ( Animal studies indicate potential for effects with respect to pregnancy, embryo-fetal development, parturition, or postnatal development. However, dose levels without observed adverse effects in animals ranged across studies from 3-32 times the maximum recommended human dose based on body surface area ( Skinoren package insert , 2016 ). Amount of azelaic acid available systemically after topical administration is minimal ( < 4%); hence, deemed low risk ( Uptodate, 2019 ).
Unknown if azelaic acid is excreted in breast milk. Amount of azelaic acid available systemically after topical administration is minimal ( < 4%); significant change from baseline azelaic acid levels in breast milk is not expected. † Animal studies have shown no adverse effects on fertility.
Animal studies have shown no adverse effects on fertility.
Benzoyl peroxide Animal studies have not been conducted. Estimated 2% of applied dose is expected to be absorbed systemically, but considered safe .
Unknown if benzoyl peroxide is excreted in breast milk. Caution should be exercised when administering to nursing women.
Limited data. Limited data.
Adapalene
Limited safety data available. Not recommended according to experts. * Case report of cerebral and ocular malformations in exposed fetus, which resulted in termination of pregnancy ( Autret et al., 1997 ) .
Excretion in breast milk is unknown. Recommendation to use with caution.
Animal studies have not shown adverse effects on fertility.
Tretinoin
Studies suggest that usage in small body surface areas are likely safe; however, not recommended according to experts. * Minimal amounts found in breast milk, not thought to be harmful to infants .
Animal studies showed no effects on fertility and general reproductive performance. No specific contraceptive precautions are necessary for men using topical tretinoin.
Animal studies showed no effects on fertility.
Isotretinoin
Isotretinoin is contraindicated in women of childbearing potential. Patients should be on two forms of contraception or abstinence at least 1 month prior, during, and 1 month after discontinuation. Associated with major fetal abnormalities, spontaneous abortions, premature births, and low IQ scores. Embryopathy has been reported even with single doses.
Excreted in breast milk. Not recommended during lactation.
No reported effects on sperm parameters and no recommendation to male patients for discontinuation when trying to conceive ( Briggs et al., 2014 ) .
Limited data available on female fertility.
Hair agents
Minoxidil (topical) Case reports of newborns with birth defects ( Smorlesi et al., 2003 ) ; hence, suggested to avoid during pregnancy.
Deemed safe by AAP. ‡ Manufacturer's animal rodent studies have shown reduction in conception rates; Limited data available in humans.
Limited data available in humans.
Finasteride Pregnant women are advised to avoid crushed or broken finasteride tablets and contact with semen from male partners exposed to finasteride, although it has been shown that pregnant women are exposed to only a negligible amount of finasteride in their male partner's semen. Rodent studies showed decreased sperm concentration but no reduction in sperm motility and fertility. In humans, gynaecomastia, impotence, and reduced sperm motility and density may occur with spironolactone at doses > 100mg/day due to decreased testosterone levels ( Millsop et al., 2013 ) .
Limited data. Abnormalities of external male genitalia were reported in animal reproduction studies.
Cosmetic agents
Botox and fillers In general, cosmetic therapy (e.g., botulinum toxin) should be avoided during pregnancy, even though data exist to suggest that risk to fetus is low. No case reports have examined outcomes of pregnant women and their children after use of hyaluronic acid, poly-L-lactic acid, calcium hydroxylapatite, or collagen fillers during pregnancy.
Use in lactating mothers is unknown.
Hydroquinone (topical)
Studies on reproduction and fertility have yielded conflicting results. Based on available data, hydroquinone use during pregnancy does not appear associated with increased risk of major malformations or other adverse effects ( Decaprio, 1999 ) . However, because of substantial absorption compared with other products, it is best to minimize exposure until further studies can confirm safety.
Excretion in breast milk is unknown.
Animal studies have yielded conflicting results with regard to reproduction.
Analgesics
Paracetamol
Analgesic of choice during pregnancy Deemed compatible by AAP Epidemiological studies have shown that in utero exposure may be associated with cryptorchidism in offspring ( Kilcoyne and Mitchell, 2017 ) .
No known effects; however, recent studies with animals and human embryonic stem cells have shown that intrauterine exposure at levels commonly observed in pregnant women may compromise female reproductive health ( Holm et al., 2016 ) . Aspirin Low-dose aspirin permissible during pregnancy; avoid during third trimester due to risk of fetal harm.
Salicylates cross the placenta and enter fetal circulation. Low dose permissible; however, alternative drugs should be considered for analgesic use.
A meta-analysis showed efficacy of low-dose aspirin in improving pregnancy rate for in vitro fertilization ( Wang et al., 2017 ) .
Human study on 7 healthy male volunteers showed possible adverse effects on fertility with high doses of aspirin ( Kershaw et al., 1987 Excretion in breast milk is unknown.
Limited data available. Limited data available.
Miscellaneous
Colchicine Colchicine is not associated with increased teratogenic risk during pregnancy ( Both et al., 2012 ) .
Excreted in breast milk; however, no adverse effects reported in infants during breastfeeding with mothers who receive 1.5 mg/day.
Meta-analysis showed no demonstrable negative effect on fertility.
Meta-analysis showed no demonstrable negative effect on fertility ( Both et al., 2012 ) .
Use of topical salicylic acid on limited areas for limited time is generally acceptable; * however, occlusive dressings should be avoided. No studies on the effects of salicylic acid on human pregnancy, but other salicylates have been associated with birth abnormalities.
Deemed safe by American Academy of Dermatology. ‡ No apparent effects on both male and female fertility.
No apparent effects on both male and female fertility. human in vitro study demonstrated that histamine had spermicidal properties, and low doses of H1 antihistamines prevented this spermicidal action ( Millsop et al., 2013 ) .
A few reported cases of improved sperm count and motility with the use of H1 antihistamines also exist. Due to insufficient data, there are no recommendations to avoid antihistamine use when planning to conceive.
Doxepin
Doxepin has been associated with fetal ileus and hypotonia in newborns when used during the third trimester; however, no congenital human malformations have been reported with use during early pregnancy. Doxepin is secreted in breast milk, and there is a case report of drowsiness, vomiting, poor feeding, and muscle hypotonia in a nursing infant after maternal use of doxepin ( Frey et al., 1999 ) . Animal studies have reported risks of impaired fertility with high doses of doxepin ( Sinequan package insert, 2007 ) .
Antimicrobials
Information on antimicrobial agents is shown in Table 4 .
Antibacterials
The choice of antibiotic in pregnancy should be governed by antibiotic sensitivities whenever possible. In general, penicillins and the erythromycin group have a history of safety during pregnancy, except for erythromycin estolate, which has risks of hepatotoxicity during the second trimester. Mupirocin is the topical agent of choice during pregnancy and lactation.
Antifungals
Oral anti-fungal agents should be avoided during pregnancy. Superficial cutaneous infections can be treated with topical agents unless the mother's health or function is severely impaired by the condition. Vulvovaginal candidiasis during pregnancy should be treated with topical agents. Treatment for onychomycosis should be best left until after pregnancy.
Antivirals
Acyclovir is preferred for the treatment of genital herpes in pregnant women because more data are available. However, valacyclovir may also be considered due to its simplified dosing schedule. Breastfeeding should be avoided if herpetic lesions are on the breast to prevent transmission to the infant.
Antiscabietics
Permethrin, topical precipitated sulphur, benzyl benzoate, and crotamiton are all considered safe for scabies therapy. The choice of treatment during pregnancy and lactation is permethrin.
Acne, hair, and cosmetic agents, and miscellaneous agents
Information on acne, hair, and cosmetic agents, and miscellaneous agents are shown in Table 5 . Topical acne agents include azelaic acid, benzoyl peroxide, adapalene, and tretinoin. Azelaic acid and benzoyl peroxide have been considered safe to use during pregnancy. Isotretinoin is contraindicated in women of childbearing potential and is associated with major fetal abnormalities, with embryopathy reported even with a single dose. Isotretinoin is excreted in breast milk and thus not recommended during lactation.
Topical and oral agents used to treat female pattern hair loss (e.g., minoxidil, finasteride, spironolactone, and dutasteride) should be avoided during pregnancy.
Lidocaine (Lignocaine) and prilocaine are not contraindicated during pregnancy and lactation for topical or intradermal use in routine biopsies and excisions. There are no studies to document prenatal fetal lidocaine levels after maternal cutaneous injection. Therefore, the usual recommended maximal doses can be used with closer monitoring. The lowest possible doses of adrenaline should be used with lidocaine.
Paracetamol is the analgesic of choice during pregnancy and lactation. Aspirin should be avoided during the third trimester due to risks of premature closure of the ductus arteriosus and excessive blood loss during delivery. Nonsteroidal anti-inflammatory agents are associated with an increased risk of spontaneous abortion during the first trimester, neonatal renal failure, and premature closure of the ductus arteriosus if used during the last trimester; hence, they should be avoided during pregnancy and lactation.
Conclusion
This new FDA ruling provides patients and prescribers with additional information to guide decision making to provide the best standard of care for both the mother and child during pregnancy and breastfeeding, as well as for patients of childbearing age. The guidelines will affect and change current practices and policies as supported by clinical data. However, this may imply increasing the responsibility of physicians to safeguard the wellbeing of their patients. Rather than depending on overly simplistic letter risk categories, dermatologists now need to make prescribing decisions based on each patient and new information provided. Ideally, pregnant patients and those who are breastfeeding or of childbearing potential should also be able to make informed decisions with regard to these issues. Overall, this new rule aims to improve safety and patient care.
